相关实验视频

Updated: Jan 11, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

亚兹罗米辛通过调节FOXO3A/CCND1信号通路来缓解烟草烟雾引起的肺衰老

Zhangrong Chen¹, Qiaoli He¹, Xiaofei Yi²

¹Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China.

International journal of chronic obstructive pulmonary disease

|November 17, 2025

概括

亚齐思罗米通过向FOXO3A/CCND1通路来缓解慢性阻塞性肺病 (COPD) 中的肺衰老,为COPD患者提供新的治疗策略.

科学领域:

肺部医学肺部医学
老年学是一门学科.
药理学药理学是指药理学的学科.

背景情况:

慢性阻塞性肺病 (COPD) 与加速的肺衰老有关.
在COPD中,阿齐思罗米可以抵消肺衰老的确切机制尚不完全理解.

研究的目的:

调查阿齐思罗米潜在缓解COPD肺衰老的机制.
探索FOXO3A/CCND1通路在阿齐思罗米对COPD的抗衰老作用中的作用.

主要方法:

网络药理学被用来预测COPD中阿齐思罗米的途径.
通过暴露于香烟烟雾的小鼠和使用香烟烟雾提取物 (CSE) 的人类支气管上皮细胞 (BEAS-2B) 建立了COPD模型.
在体外和体外评估了阿齐思罗米对细胞衰老标志物,衰老相关分泌表型 (SASP) 细胞因子,FOXO3A和CCND1的影响.

主要成果:

慢性肺炎患者和暴露于香烟烟雾的小鼠表现出肺衰老标志物的增加 (p53,p21,CCND1) 和FOXO3A表达的减少.
在COPD模型中,阿兹胺治疗降低了SASP分泌,降低了p53,p21和CCND1的表达,同时增加了FOXO3A.
在体外,阿齐思罗米预条件治疗逆转了CSE诱导的衰老标志物和CCND1的增加,并恢复了FOXO3A水平.

结论:

阿齐思罗米表现出与COPD相关的抗衰老特性.
FOXO3A/CCND1通路是阿齐思罗米在COPD中肺部抗衰老作用的关键调解者.
这些发现表明,阿齐思罗米在治疗COPD相关的肺衰老方面具有新的治疗潜力.

关键词:

慢性慢性肺炎是一种慢性慢性肺炎,COPD是一种慢性肺炎.在FOXO3A/CCND1路径中,亚齐特罗米辛是一种亚齐特罗米辛.香烟的烟雾,就是烟雾.衰老是一种老化.

更多相关视频

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...